Analysis of influence of omega-3-polyunsaturated fatty acids on biochemical values of the blood and adipokines content in patients with arterial hypertension, osteoarthritis and its combination with optimal and increased body weight
DOI:
https://doi.org/10.15587/2313-8416.2016.61138Keywords:
arterial hypertension, osteoarthritis, overweight, leptin, adiponectin, hyperglycemia, omega-3-polyunsaturated fatty acidsAbstract
Combination of arterial hypertension and osteoarthritis especially on the background of overweight leads to the heavier clinical course of diseases.
The aim of research was to study is it any therapeutic advantage in the use of omega-3-polyunsaturated fatty acids (PUFA) in patients with arterial hypertension (AH), osteoarthritis (OA) and its combination in the aspect of hypolipidemic influence and adipokines level.
Materials: There were examined 100 patients, 35 – with AH, 35 – with OA and 30 – with AH in combination with OA. The men-women ratio was 2,5:1, the mean age – 49,6±8,9 years. The mean AH duration was 7,4±3,8 years, the clinical presentation of disease corresponded with II stage. The prescription of osteoarthritis was 8,4±4,6 years the clinical presentation corresponded with OA 2-3 stages without the signs of synovitis.
The control examinations were carried out in the group of practically healthy persons (n=22) comparable with the patients of other groups on age and sex. The blood for biochemical studies was taken on the first day of being in hospital approximately at the same time 9-10 a.m. fasting. The adipokines level was detected using immune-enzyme analysis.
Depending on nosology all patients received the basal therapy that included: at AH – ACE inhibitors (lisinopril, enalapril), at OA – non-steroid anti-inflammatory preparations (meloxicam, ibuprofen, diclofenak sodium), chondroprotectors (mukosat, alflutop). Patients with the signs of dyslipidemia received hypolipidemic medical preparations (rosuvastatin).
All patients with signs of hyperglycemia were randomly divided in two groups that included equal number of persons with all variants of nosologies. The group of comparison (50 persons) received depending on nosology basal therapy that included: at AH – ACE inhibitors (lisinopril), at OA – non-steroid anti-inflammatory preparations (meloxicam, ibuprofen, diclofenak sodium), chondroitin sulfate preparations (mukosat, alflutop). Patients with the signs of dyslipidemia received hypolipidemic medical preparations (rosuvastin). Patients of the main group (50 persons) were additionally prescribed with preparation that contains omega-3-PUFA – Epadol Neo as a source of omega-3-PUFA, 1 capsule 2 times for day for two month.
All data were assessed using methods of variation analysis.
Results. The standard therapy of the group of comparison partially improved dyslipidemic changes. The content of general cholesterol was decreased from 5,8±0,41 to 4,7±0,32 mmol/l (p<0,05). The use of omega-3-PUFA resulted in further improvement (4.4±0,22 mmol/l) in the main group. The same positive dynamics was detected for other indices – the high-density lipoprotein (HDL) content increased after treatment from 1,5±0,11 to 1,6±0,21 mmol/l in the group of comparison and to 1,76±0,13 (p<0,05) in the main group; triglycerides content in the main group and in the group of comparison came back to the normal values: 2,3±0,14 mmol/l before treatment; 1,8±0,08 mmol/l (p<0,05) and 1,6±0,01 mmol/l (p<0,05) in the group of comparison and іn the main one respectively.
The treatment with the use of standard preparations has no influence on both adipokines level. Additional use of omega-3-PUFA significantly and reliably decreased the leptin content in the blood of patients with AH and overweight: from 49,2±5,48 ng/ml to 16,5±3,48 ng/ml (p<0,05). The less dynamics was observed in patients with OA and combination of AH and OA: the decrease of leptin level in blood from 40,5±4,3 to 34,1±4,94 ng/ml (p<0,05) and from 55,4±6,62 ng/ml to 38,6±3,62 ng/ml (p<0,05).
Adiponectin content was sensitive to treatment. Positive statistically reliable changes were observed in patients of the main group with all studied pathologies (isolated AH, OA and its combination) after 2 month of use of omega-3-PUFA.
Conclusions: The use of omega-3-PUFA in the complex treatment is effective for patients with AH and AH with concomitant OA as to hyperlipidemia correction. It favors the renewal of natural balance of adipokines: diminishes the leptin level, increases the adiponectin content
References
Molinar-Toribio, E., Pérez-Jiménez, J., Ramos-Romero, S., Romeu, M., Giralt, M., Taltavull, N. et. al (2015). Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome. British Journal of Nutrition, 113 (06), 878–887. doi: 10.1017/s0007114514004437
Simonds, S. E., Pryor, J. T., Ravussin, E., Greenway, F. L., Dileone, R., Allen, A. M. et. al (2014). Leptin Mediates the Increase in Blood Pressure Associated with Obesity. Cell, 159 (6), 1404–1416. doi: 10.1016/j.cell.2014.10.058
Tagetti, A., Ericson, U., Montagnana, M., Danese, E., Almgren, P., Nilsson, P. et. al (2015). Intakes of omega-3 polyunsaturated fatty acids and blood pressure change over time: Possible interaction with genes involved in 20-HETE and EETs metabolism. Prostaglandins & Other Lipid Mediators, 120, 126–133. doi: 10.1016/j.prostaglandins.2015.05.003
Gholamin, S., Razavi, S. M., Taghavi-Garmestani, S. M. et. al (2014). Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy. Iran J Kidney Dis., 8 (3), 201–206.
Vafeiadou, K., Weech, M., Altowaijri, H., Todd, S., Yaqoob, P., Jackson, K. G., Lovegrove, J. A. (2015). Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. American Journal of Clinical Nutrition, 102 (1), 40–48. doi: 10.3945/ajcn.114.097089
Lee, T. C., Ivester, P., Hester, A. G., Sergeant, S., Case, L., Morgan, T. et. al (2014). The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population. Lipids in Health and Disease, 13 (1), 196. doi: 10.1186/1476-511x-13-196
Colussi, G., Catena, C., Mos, L., Sechi, L. A. (2015). The Metabolic Syndrome and the Membrane Content of Polyunsaturated Fatty Acids in Hypertensive Patients. Metabolic Syndrome and Related Disorders, 13 (8), 343–351. doi: 10.1089/met.2015.0025
Colussi, G., Catena, C., Dialti, V., Mos, L., Sechi, L. A. (2015). The vascular response to vasodilators is related to the membrane content of polyunsaturated fatty acids in hypertensive patients. Journal of Hypertension, 33 (5), 993–1000. doi: 10.1097/hjh.0000000000000495
Mendel, O. I., Naumov, A. V., Alekseeva, L. I. et. al (2010). Osteoarthritis as a risk factor for cardiovascular accidents. RMJ, 6, 400.
Krysiak, R., Zmuda, W., Okopien, B. (2014). The Effect of Simvastatin-Ezetimibe Combination Therapy on Adipose Tissue Hormones and Systemic Inflammation in Patients with Isolated Hypercholesterolemia. Cardiovascular Therapeutics, 32 (2), 40–46. doi: 10.1111/1755-5922.12057
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Наталія Валентинівна Швець, Тетяна Олександрівна Ілащук, Оксана Павлівна Микитюк
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
